ZA200207217B - Method for reducing or eliminating smoking. - Google Patents
Method for reducing or eliminating smoking. Download PDFInfo
- Publication number
- ZA200207217B ZA200207217B ZA200207217A ZA200207217A ZA200207217B ZA 200207217 B ZA200207217 B ZA 200207217B ZA 200207217 A ZA200207217 A ZA 200207217A ZA 200207217 A ZA200207217 A ZA 200207217A ZA 200207217 B ZA200207217 B ZA 200207217B
- Authority
- ZA
- South Africa
- Prior art keywords
- time
- nicotine
- tobacco
- unit
- predetermined period
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 70
- 230000000391 smoking effect Effects 0.000 title claims description 40
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims description 139
- 229960002715 nicotine Drugs 0.000 claims description 129
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims description 129
- 241000208125 Nicotiana Species 0.000 claims description 95
- 235000002637 Nicotiana tabacum Nutrition 0.000 claims description 95
- 230000002618 waking effect Effects 0.000 claims description 10
- 230000003247 decreasing effect Effects 0.000 claims description 7
- 210000004400 mucous membrane Anatomy 0.000 claims description 5
- 239000007937 lozenge Substances 0.000 claims description 3
- 229940097496 nasal spray Drugs 0.000 claims description 3
- 239000007922 nasal spray Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000009467 reduction Effects 0.000 description 24
- 229940068196 placebo Drugs 0.000 description 9
- 239000000902 placebo Substances 0.000 description 9
- 230000005586 smoking cessation Effects 0.000 description 9
- 235000019504 cigarettes Nutrition 0.000 description 8
- 229940087730 nicorette Drugs 0.000 description 7
- 238000011282 treatment Methods 0.000 description 6
- 238000002670 nicotine replacement therapy Methods 0.000 description 5
- 235000019788 craving Nutrition 0.000 description 4
- 206010057852 Nicotine dependence Diseases 0.000 description 3
- 230000008030 elimination Effects 0.000 description 3
- 238000003379 elimination reaction Methods 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 229960001698 nicotine polacrilex Drugs 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 2
- 238000000959 Cochran–Mantel–Haenszel (CMH) test Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- 230000001055 chewing effect Effects 0.000 description 2
- 229940112822 chewing gum Drugs 0.000 description 2
- 235000015218 chewing gum Nutrition 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 238000011422 pharmacological therapy Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- GRZMOSSVIPFGFF-GNJLJDPWSA-N 2-[(2r,6s)-6-[(2s)-2-hydroxy-2-phenylethyl]-1-methylpiperidin-2-yl]-1-phenylethanone;sulfuric acid Chemical compound OS(O)(=O)=O.C1([C@@H](O)C[C@H]2N([C@H](CCC2)CC(=O)C=2C=CC=CC=2)C)=CC=CC=C1.C1([C@@H](O)C[C@H]2N([C@H](CCC2)CC(=O)C=2C=CC=CC=2)C)=CC=CC=C1 GRZMOSSVIPFGFF-GNJLJDPWSA-N 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- 208000025569 Tobacco Use disease Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 238000013542 behavioral therapy Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000015111 chews Nutrition 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000009223 counseling Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 235000019505 tobacco product Nutrition 0.000 description 1
- 238000012549 training Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/465—Nicotine; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Manufacture Of Tobacco Products (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/504,560 US6660754B1 (en) | 2000-02-15 | 2000-02-15 | Method for reducing or eliminating smoking |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200207217B true ZA200207217B (en) | 2003-08-04 |
Family
ID=24006789
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200207217A ZA200207217B (en) | 2000-02-15 | 2002-09-09 | Method for reducing or eliminating smoking. |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US6660754B1 (https=) |
| EP (1) | EP1265610A4 (https=) |
| JP (1) | JP2003522789A (https=) |
| KR (1) | KR20020075795A (https=) |
| CN (1) | CN1400901A (https=) |
| AR (1) | AR032440A1 (https=) |
| AU (1) | AU782403B2 (https=) |
| BR (1) | BR0108318A (https=) |
| CA (1) | CA2400353A1 (https=) |
| CO (1) | CO5261581A1 (https=) |
| CZ (1) | CZ20022766A3 (https=) |
| EA (1) | EA004184B1 (https=) |
| EG (1) | EG22199A (https=) |
| HU (1) | HUP0301131A3 (https=) |
| MY (1) | MY127259A (https=) |
| NZ (1) | NZ520586A (https=) |
| PE (1) | PE20011221A1 (https=) |
| PL (1) | PL357013A1 (https=) |
| WO (1) | WO2001060364A1 (https=) |
| ZA (1) | ZA200207217B (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050112148A1 (en) * | 2003-11-21 | 2005-05-26 | Dmitruk Victor M. | Habit based self-help method for smoking cessation |
| US20070134169A1 (en) * | 2005-12-11 | 2007-06-14 | Rabinoff Michael D | Methods for smoking cessation or alcohol cessation or other addiction cessation |
| US20080230078A1 (en) * | 2007-03-19 | 2008-09-25 | Oby George Tolman | Method of smoking cessation |
| EP2515918B1 (en) * | 2009-12-21 | 2014-10-08 | RCP Development, Inc. | Smoking cessation lozenge containing tobacco alkaloid and silver salt |
| US20110268809A1 (en) | 2010-04-28 | 2011-11-03 | Paul Andrew Brinkley | Nicotine-Containing Pharmaceutical Compositions |
| US20110274628A1 (en) | 2010-05-07 | 2011-11-10 | Borschke August J | Nicotine-containing pharmaceutical compositions |
| CN101858902B (zh) * | 2010-06-01 | 2012-12-12 | 中国科学院广州地球化学研究所 | 一种结合碳同位素比值的土壤蚀变碳酸盐的测量方法 |
| US20130078307A1 (en) | 2011-09-22 | 2013-03-28 | Niconovum Usa, Inc. | Nicotine-containing pharmaceutical composition |
| US9907748B2 (en) | 2011-10-21 | 2018-03-06 | Niconovum Usa, Inc. | Excipients for nicotine-containing therapeutic compositions |
| US9763928B2 (en) | 2012-02-10 | 2017-09-19 | Niconovum Usa, Inc. | Multi-layer nicotine-containing pharmaceutical composition |
| US20140255452A1 (en) | 2013-03-11 | 2014-09-11 | Niconovum Usa, Inc. | Method and apparatus for differentiating oral pouch products |
| US20170165252A1 (en) | 2015-12-10 | 2017-06-15 | Niconovum Usa Inc. | Protein-enriched therapeutic composition |
| CN108685184B (zh) * | 2017-04-11 | 2020-06-16 | 常州市派腾电子技术服务有限公司 | 辅助戒烟方法及辅助戒烟装置 |
| CN107149028A (zh) * | 2017-04-17 | 2017-09-12 | 廖华勇 | 内含微量烟草气味的香口胶 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5055478A (en) | 1986-06-19 | 1991-10-08 | Cooper Thomas M | Method for stopping smoking |
| US5488962A (en) | 1990-10-10 | 1996-02-06 | Perfetti, S.P.A. | Chewing gum which is a substitute for tobacco smoke |
| AR030092A1 (es) * | 2000-08-02 | 2003-08-13 | Smithkline Beecham Corp | Metodo para reducir o eliminar el fumar |
-
2000
- 2000-02-15 US US09/504,560 patent/US6660754B1/en not_active Expired - Lifetime
-
2001
- 2001-02-13 AR ARP010100637A patent/AR032440A1/es unknown
- 2001-02-13 MY MYPI20010641A patent/MY127259A/en unknown
- 2001-02-13 PE PE2001000154A patent/PE20011221A1/es not_active Application Discontinuation
- 2001-02-14 EG EG20010130A patent/EG22199A/xx active
- 2001-02-14 CO CO01011530A patent/CO5261581A1/es not_active Application Discontinuation
- 2001-02-15 EP EP01910708A patent/EP1265610A4/en not_active Withdrawn
- 2001-02-15 KR KR1020027010559A patent/KR20020075795A/ko not_active Withdrawn
- 2001-02-15 CA CA002400353A patent/CA2400353A1/en not_active Abandoned
- 2001-02-15 HU HU0301131A patent/HUP0301131A3/hu unknown
- 2001-02-15 BR BR0108318-0A patent/BR0108318A/pt not_active Application Discontinuation
- 2001-02-15 CN CN01804937A patent/CN1400901A/zh active Pending
- 2001-02-15 EA EA200200765A patent/EA004184B1/ru not_active IP Right Cessation
- 2001-02-15 CZ CZ20022766A patent/CZ20022766A3/cs unknown
- 2001-02-15 AU AU38289/01A patent/AU782403B2/en not_active Expired
- 2001-02-15 PL PL01357013A patent/PL357013A1/xx not_active Application Discontinuation
- 2001-02-15 WO PCT/US2001/004798 patent/WO2001060364A1/en not_active Ceased
- 2001-02-15 JP JP2001559461A patent/JP2003522789A/ja not_active Withdrawn
- 2001-02-15 NZ NZ520586A patent/NZ520586A/en not_active IP Right Cessation
-
2002
- 2002-09-09 ZA ZA200207217A patent/ZA200207217B/en unknown
-
2003
- 2003-09-24 US US10/670,922 patent/US20040058966A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EA004184B1 (ru) | 2004-02-26 |
| AU3828901A (en) | 2001-08-27 |
| BR0108318A (pt) | 2003-02-18 |
| US20040058966A1 (en) | 2004-03-25 |
| MY127259A (en) | 2006-11-30 |
| KR20020075795A (ko) | 2002-10-05 |
| US6660754B1 (en) | 2003-12-09 |
| CA2400353A1 (en) | 2001-08-23 |
| CO5261581A1 (es) | 2003-03-31 |
| NZ520586A (en) | 2004-11-26 |
| PL357013A1 (en) | 2004-07-12 |
| CZ20022766A3 (cs) | 2003-05-14 |
| HUP0301131A3 (en) | 2004-01-28 |
| JP2003522789A (ja) | 2003-07-29 |
| HUP0301131A2 (hu) | 2003-08-28 |
| EA200200765A1 (ru) | 2003-02-27 |
| AR032440A1 (es) | 2003-11-12 |
| CN1400901A (zh) | 2003-03-05 |
| EP1265610A1 (en) | 2002-12-18 |
| WO2001060364A1 (en) | 2001-08-23 |
| EP1265610A4 (en) | 2008-04-02 |
| AU782403B2 (en) | 2005-07-28 |
| PE20011221A1 (es) | 2002-02-07 |
| EG22199A (en) | 2002-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Schneider et al. | Nicotine gum in smoking cessation: a placebo-controlled, double-blind trial | |
| US6660754B1 (en) | Method for reducing or eliminating smoking | |
| Myles et al. | Effectiveness of bupropion as an aid to stopping smoking before elective surgery: a randomised controlled trial | |
| Bolliger | Practical experiences in smoking reduction and cessation | |
| Glover et al. | A multicenter phase 3 trial of lobeline sulfate for smoking cessation | |
| Lillington et al. | Smoking cessation: techniques and benefits | |
| Sims et al. | Pharmacotherapy for treating tobacco dependence: what is the ideal duration of therapy? | |
| US6224897B1 (en) | Methods to abate the use of tobacco by humans | |
| Prignot | Pharmacological approach to smoking cessation | |
| Corelli et al. | Medications for smoking cessation | |
| AU2001284704B2 (en) | Method for reducing or eliminating smoking | |
| Tønnesen | Smoking cessation programs | |
| US20040024028A1 (en) | Method for reducing or eliminating smoking | |
| AU2001284704A1 (en) | Method for reducing or eliminating smoking | |
| Bhattacharyya et al. | Therapy for Cessation of Smoking | |
| Ostrowski et al. | Pharmacologic management of patients using smoking cessation aids | |
| Burkett | The use of the nicotine inhaler in smoking cessation | |
| Coulehan | The doctor's wife | |
| Asadi et al. | A Narrative Review on Smoking Cessation Pharmacotherapy. To-bacco and Health 2023; 2 (4): 155-162 | |
| Bailey et al. | Pharmacologic approaches to smoking cessation | |
| Ellingrod | Smoking cessation: What to tell patients about over-the-counter treatments | |
| Corelli | Medicine Cabinet | |
| Lauro et al. | Update on the treatment of smoking dependence | |
| Joshi | Nicotine Replacement Therapy-A Review | |
| Shiffman et al. | Nicotine Delivery Systems |